Ovarian cancer test could be gold standard in three years, says HealthLinx
This article was originally published in Clinica
HealthLinx's second-generation ovarian cancer test could be the industry gold standard within the next three years, the Australian firm told Clinica. Futhermore, the company believes that its technology may have the potential to deliver the world's first community-based screening test for the disease.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.